联合检测p504s、34βE12在前列腺癌中的表达及临床意义

Combined detection of p504s、34βE12 expression in prostate cancer and its clinical significance

目的探讨联合检测p504s、34βE12在前列腺癌变组织中的表达及临床意义。方法采用免疫组化LDP法,检测p504s和34βE12在前列腺良恶性病变组织中的表达情况。结果49例前列腺癌(Pca)组织中p504s的阳性表达率为93.88%(46/49),未见34βE12表达;30例良性前列腺增生(BPH)组织中的34βE12均呈阳性表达(30/30),而p504s均未见表达,两种蛋白在Pca、BPH组织中的阳性表达率差异有统计学意义(P<0.05);p504s的阳性表达水平与Pca的病理分级和临床分期均呈正相关(P<0.05)。结论p504s是Pca敏感而特异性的标记物,联合检测p504s、34βE12可极大地提高前列腺癌的诊断准确率。

Objective To evaluate the expression and clinical application of p504s and 34βE12 in benign and malignant prostate lesions.Methods Immunohistochemical labeled dextran polymer （LDP） method was used to detect the expression of p504s and 34βE12 in benign and malignant prostate lesions.Results The positive expression rate of p504s in the 49 cases of Prostate Cancer （Pca） tissues was 93.88% （46/49）.No expression of 34βE12 was detected.The positive expression rate of 34βE12 was detected in the 30 cases （30/30） of benign prostatic hyperplasia （BPH）.No expression of p504s was in BPH.There was significant difference （P 〈 0.05） between the 2 proteins＇ positive expression in Pca and BPH tissues.The expression of p504s was positively correlated to tumor pathological grades （P 〈 0.05） and tumor clinical stages （P 〈 0.05）.Conclusions p504s is a sensitive and specific prostate cancer （Pca） marker.Combined detection of p504s and 34βE12 can greatly improve the diagnosis of prostatic cancer.